CN1176664C - Medicine for treating bacillary dysentery and enteritis - Google Patents
Medicine for treating bacillary dysentery and enteritis Download PDFInfo
- Publication number
- CN1176664C CN1176664C CNB021449643A CN02144964A CN1176664C CN 1176664 C CN1176664 C CN 1176664C CN B021449643 A CNB021449643 A CN B021449643A CN 02144964 A CN02144964 A CN 02144964A CN 1176664 C CN1176664 C CN 1176664C
- Authority
- CN
- China
- Prior art keywords
- medicine
- enteritis
- bismuth subcarbonate
- gentamycin sulfate
- bacillary dysentery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a medicine for treating enteritis and bacillary dysentery, which has gentamycin sulfate and bismuth subcarbonate as main components, wherein the content range of the gentamycin sulfate is from 20 mg to 200 mg, and the content range of the bismuth subcarbonate is from 200 mg to 2000 mg. The medicine has the advantages of obvious curative effect and no toxic side effect, has specific effects for treating intestinal canal diseases, such as enteritis, bacillary dysentery and chronic ulcerative colitis, and solves the problem that original Changyanling is unfavorable for preventing and curing tuberculosis because the original Changyanling contains rifampicin which can lower medicinal effects for treating tuberculosis.
Description
(1) technical field
The present invention relates to a kind of medicine, particularly relate to a kind of medicine for the treatment of enteritis, bacillary dysentery.
(2) technical background
The common drug of treatment enteritis, bacillary dysentery is a gentamycin sulfate and bismuth subcarbonate capsules, and its Main Ingredients and Appearance is rifampicin and bismuth subnitrate.Because rifampicin is an antituberculotics, often takes the gentamycin sulfate and bismuth subcarbonate capsules that contains rifampicin and easily produces drug resistance, is unfavorable for control lungy; In addition, when using, become nitrite because of escherichia coli in the intestinal etc. can reduce nitrate ion, can cause poisoning, particularly to children's, so the use of this medicine has very big limitation.
(3) summary of the invention
The technical problem to be solved in the present invention provides a kind of evident in efficacyly, control lungy is not produced the medicine of chemical sproof treatment enteritis bacillary dysentery.
The technical scheme that adopts:
A kind of medicine for the treatment of enteritis, bacillary dysentery, its Main Ingredients and Appearance are gentamycin sulfate and bismuth subcarbonate (formal name used at school is a bismuth subcarbonate), and the compatibility of gentamycin sulfate and bismuth subcarbonate is: gentamycin sulfate is 20mg～200mg; Bismuth subcarbonate be 200mg～2000mg.
Described a kind of medicine for the treatment of the enteritis bacillary dysentery, Powdered or graininess, its dosage form are capsule or tablet.
A kind of production method for the treatment of the medicine of enteritis, bacillary dysentery of the present invention is a known technology, promptly is that gentamycin sulfate and bismuth subcarbonate are got it filled by compatibility, carries out physical mixed, can be made into wafer, tablet.When making various dosage form, can add appropriate amount of auxiliary materials, as can to add an amount of concentration when making wafer be 70-99 ° ethanol, can add the appropriate amount of starch slurry when making tablet, as add the starch slurry of the gross weight 10% of being used as medicine, owing to be to adopt known technology to produce the medicine of treatment enteritis bacillary dysentery of the present invention, so production method is not done the detail explanation.
The pharmacological action of Main Ingredients and Appearance of the present invention:
Gentamycin sulfate is the aminoglycoside medicine, various gram-negative bacterias and gram-positive bacteria all there are good antibacterial action, good effect are arranged various enterobacteriaceae lactobacteriaceaes such as escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Enterobacter, Serratia and Aerugo are false unicellular etc.Neisseria and hemophilus influenza are to this product medium sensitivity.Brucella, bacillus pestis, acinetobacter, campylobacter fetus also there is certain effect.Methicillin-sensitivity bacterial strain in the staphylococcus (comprising staphylococcus aureus and coagulase negative staphylococcus) about 80% there is good antibacterial action.
Bismuth subcarbonate can play the antacid and the astriction of protectiveness at gastrointestinal mucosa, can reach anti-diarrhea effect by the stimulation that reduces intestinal, prevents body excessively dehydration and water-electrolyte metabolism imbalance.
Indication of the present invention:
Be applicable to the gastrointestinal infection due to the sensitive bacterial; The chronic gastritis of overbased acidic, Peptic Ulcers have antiacid effect.This product also can be used for preparing before the colonic operation.
Usage and dosage:
Oral, be grown up one time 2～3,3 times on the one; 1 of child one time, 3 times on the one; The continuous use person, a course of treatment should not be above 10 days.
The present invention compares with similar medicine has following advantage and beneficial effect:
1, owing to selects for use gentamycin sulfate and bismuth subcarbonate to form this medicine with broad-spectrum antiseptic antiinflammation, therefore, intestinal tract disease such as enteritis, bacillary dysentery, chronic ulcerative colitis there is specially good effect, and determined curative effect, solved former gentamycin sulfate and bismuth subcarbonate capsules because of containing rifampicin, easily produce, be unfavorable for the problem of control lungy drug resistance lungy;
2, to adopt bismuth subcarbonate be primary raw material in the present invention, during use, has no side effect, and the child also can take, and its treatment diarrhoea, colitis and Thyme Extract all obviously are better than bismuth subnitrate;
3, from gentamycin sulfate and bismuth subcarbonate capsule (treatment group, every sulfur acid gentamycin 40mg, bismuth subcarbonate 600mg) and gentamycin sulfate and bismuth subnitrate capsule (matched group, every sulfur acid gentamycin 40mg, bismuth subnitrate 150mg) clinical test results that is used for the treatment of acute enteritis, acute bacillary dysentery as can be seen, gentamycin sulfate and bismuth subcarbonate capsule for treating acute enteritis, acute bacillary dysentery have significant curative effect, and curative effect is better than contrasting medicine.Clinical test results sees Table one, table two:
Table one
Divide into groups routine number of project is cured produce effects enabledisable total effective rate
Treatment organizes 32 20 561 96.9%
Acute enteritis
Matched group 18 10 431 94.4%
Table two
Divide into groups routine number of project is cured produce effects enabledisable total effective rate
Treatment organizes 32 18 572 93.8%
Acute bacillary dysentery
Matched group 18 11 232 88.9%
(4) specific embodiment
Embodiment one
Get gentamycin sulfate 20mg and bismuth subcarbonate 200mg and mix, make powder, in incapsulating, make capsule with appropriate amount of auxiliary materials (ethanol).
Embodiment two
Get gentamycin sulfate 20mg and bismuth subcarbonate 200mg, mix, make granule, be pressed into tablet with appropriate amount of auxiliary materials (10% starch slurry).
Embodiment three
Get gentamycin sulfate 30mg and bismuth subcarbonate 400mg, mix, make powder, in incapsulating, make capsule with appropriate amount of auxiliary materials (ethanol).
Embodiment four
Get gentamycin sulfate 30mg and bismuth subcarbonate 400mg, mix, make granule, be pressed into tablet with appropriate amount of auxiliary materials (10% starch slurry).
Embodiment five
Get gentamycin sulfate 40mg and bismuth subcarbonate 600mg, mix, make powder, in incapsulating, make capsule with appropriate amount of auxiliary materials (ethanol).
Embodiment six
Get gentamycin sulfate 40mg and bismuth subcarbonate 600mg, mix, make granule, be pressed into tablet with appropriate amount of auxiliary materials (10% starch slurry).
Embodiment seven
Get gentamycin sulfate 50mg and bismuth subcarbonate 800mg and mix, make powder, in incapsulating, make capsule with appropriate amount of auxiliary materials (ethanol).
Embodiment eight
Get gentamycin sulfate 50mg and bismuth subcarbonate 800mg, mix, make granule, be pressed into tablet with appropriate amount of auxiliary materials (10% starch slurry).
Embodiment nine
Get gentamycin sulfate 60mg and bismuth subcarbonate 1000mg, mix, make powder, in incapsulating, make capsule with appropriate amount of auxiliary materials (ethanol).
Embodiment ten
Get gentamycin sulfate 60mg and bismuth subcarbonate 1000mg, mix, make granule, be pressed into tablet with appropriate amount of auxiliary materials (10% starch slurry).
Embodiment 11
Get gentamycin sulfate 200mg and bismuth subcarbonate 200mg, mix, make powder, in incapsulating, make capsule with appropriate amount of auxiliary materials (ethanol).
Embodiment 12
Get gentamycin sulfate 200mg and bismuth subcarbonate 200mg, mix, make granule, be pressed into tablet with appropriate amount of auxiliary materials (10% starch slurry).
Embodiment 13
Get gentamycin sulfate 20mg and bismuth subcarbonate 2000mg, mix, make powder, in incapsulating, make capsule with appropriate amount of auxiliary materials (ethanol).
Embodiment 14
Get gentamycin sulfate 20mg and bismuth subcarbonate 2000mg, mix, make granule, be pressed into tablet with appropriate amount of auxiliary materials (10% starch slurry).
Claims (10)
1, a kind of medicine for the treatment of enteritis, bacillary dysentery can be wafer or tablet, it is characterized in that its Main Ingredients and Appearance is gentamycin sulfate and bismuth subcarbonate, and its compatibility is: gentamycin sulfate 20mg～200mg; Bismuth subcarbonate 200mg～2000mg.
2, a kind of medicine for the treatment of enteritis, bacillary dysentery according to claim 1 is characterized in that being mixed with appropriate amount of auxiliary materials ethanol by gentamycin sulfate 20mg, bismuth subcarbonate 200mg, makes powder, in incapsulating, makes capsule.
3, a kind of medicine for the treatment of enteritis, bacillary dysentery according to claim 1 is characterized in that being mixed with the 22mg starch slurry by gentamycin sulfate 20mg, bismuth subcarbonate 200mg, makes granule, is pressed into tablet.
4, a kind of medicine for the treatment of enteritis, bacillary dysentery according to claim 1 is characterized in that being mixed with appropriate amount of auxiliary materials ethanol by gentamycin sulfate 30mg and bismuth subcarbonate 400mg, makes powder, in incapsulating, makes capsule.
5, a kind of medicine for the treatment of enteritis, bacillary dysentery according to claim 1 is characterized in that being mixed with the 43mg starch slurry by gentamycin sulfate 30mg and bismuth subcarbonate 400mg, makes granule, is pressed into tablet.
6. a kind of medicine for the treatment of enteritis, bacillary dysentery according to claim 1 is characterized in that being mixed with appropriate amount of auxiliary materials ethanol by gentamycin sulfate 40mg and bismuth subcarbonate 600mg, makes powder, in incapsulating, makes capsule.
7, a kind of medicine for the treatment of enteritis, bacillary dysentery according to claim 1 is characterized in that being mixed with the 64mg starch slurry by gentamycin sulfate 40mg and bismuth subcarbonate 600mg, makes granule, is pressed into tablet.
8. a kind of medicine for the treatment of enteritis, bacillary dysentery according to claim 1 is characterized in that being mixed with appropriate amount of auxiliary materials ethanol by gentamycin sulfate 50mg and bismuth subcarbonate 800mg, makes powder, in incapsulating, makes capsule.
9. a kind of medicine for the treatment of enteritis, bacillary dysentery according to claim 1 is characterized in that being mixed with the 85mg starch slurry by gentamycin sulfate 50mg and bismuth subcarbonate 800mg, makes granule, is pressed into tablet.
10. a kind of medicine for the treatment of enteritis, bacillary dysentery according to claim 1 is characterized in that being mixed with appropriate amount of auxiliary materials ethanol by gentamycin sulfate 60mg and bismuth subcarbonate 1000mg, makes powder, in incapsulating, makes capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021449643A CN1176664C (en) | 2002-12-19 | 2002-12-19 | Medicine for treating bacillary dysentery and enteritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021449643A CN1176664C (en) | 2002-12-19 | 2002-12-19 | Medicine for treating bacillary dysentery and enteritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1424048A CN1424048A (en) | 2003-06-18 |
| CN1176664C true CN1176664C (en) | 2004-11-24 |
Family
ID=4750721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021449643A Expired - Fee Related CN1176664C (en) | 2002-12-19 | 2002-12-19 | Medicine for treating bacillary dysentery and enteritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1176664C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101899492B (en) * | 2009-05-27 | 2013-01-09 | 华北制药集团制剂有限公司 | Method for measuring potency of gentamycin sulfate and bismuth carbonate capsules |
| CN102048709B (en) * | 2010-12-17 | 2013-02-20 | 蚌埠丰原涂山制药有限公司 | Gentamycin sulfate capsule and preparation method thereof |
| CN102727521B (en) * | 2012-06-13 | 2013-07-24 | 辽宁王牌速效制药有限公司 | Preparation method of gentamycin bismuth carbonate capsule content intestinal release pellets |
-
2002
- 2002-12-19 CN CNB021449643A patent/CN1176664C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1424048A (en) | 2003-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1289084C (en) | Pharmaceutical formulation | |
| CN1254247C (en) | Antibiotic action enhancing medicinal composition | |
| CN1176664C (en) | Medicine for treating bacillary dysentery and enteritis | |
| Neu | Fosfomycin trometamol versus amoxycillin–single-dose multicenter study of urinary tract infections | |
| KR20120051776A (en) | Eradicating agent and eradication method for helicobacter pylori | |
| CN1152258A (en) | Method and composition for increasing calcium uptake | |
| CN1830440A (en) | Metronidazule injection and its preparation method and use | |
| CN1068519C (en) | Medicinal composition for curing ulcer of upper digestive tract and effectively inhibiting recurrance thereof | |
| TW201803558A (en) | Intestinal environment-improving agent | |
| CN100342860C (en) | Actacid composition | |
| Sande | Antimicrobial therapy for two serious bacterial infections: enterococcal endocarditis and nosocomial pneumonia | |
| WO2020211708A1 (en) | Use of anionic clay in preparing lead-removing medicament | |
| CN1096446A (en) | Compound flavescent sophora root injection for animals | |
| CN1070053C (en) | Method for preparing butethanol of injection | |
| CN1188000A (en) | Intestinal microecological preparation | |
| CN1167424C (en) | Notoginsenoside enteric-coated tablet | |
| CN1186022C (en) | Medicine for teating oral disease | |
| CN1537541A (en) | Applicaton of montmorillonite inpreparing medicine | |
| WO2019126910A1 (en) | Composition comprising piperacillin, pharmaceutical preparation thereof and use thereof | |
| CN1442138A (en) | Fukangzuo injection fluid and its preparation method | |
| CN1803148A (en) | Stomatocace-treating medicine and its preparation method | |
| CN1191722A (en) | Improved Amoxyicillin and Cleve's acid compound preparation | |
| CN1843372A (en) | Pharmaceutical compositions separately constituted by ambroxol and two other antibacterials | |
| RU2424801C1 (en) | Medication for treatment of infectios diseases | |
| CN1416815A (en) | Compound prepn containing prostaglandin E1, prostaglandin A1 and prostaglandin B1 and its prepn process and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: HULUDAO GUODI PHARMACEUTICAL Co.,Ltd. Assignor: Zhang Zhongyi Contract record no.: 2011210000096 Denomination of invention: Medicine for treating bacillary dysentery and enteritis Granted publication date: 20041124 License type: Exclusive License Open date: 20030618 Record date: 20110706 |
|
| ASS | Succession or assignment of patent right |
Owner name: GUODI PHARMACEUTICAL CO., LTD., HULUDAO Free format text: FORMER OWNER: ZHANG ZHONGYI Effective date: 20140414 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 125200 HULUDAO, LIAONING PROVINCE TO: 125001 HULUDAO, LIAONING PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140414 Address after: 125001 Huludao province Liaoning City Nanpiao District Gaoqiao Town Patentee after: HULUDAO GUODI PHARMACEUTICAL Co.,Ltd. Address before: 125200 Longwan Huludao New District Haibin road Huludao Bohai Liaoning Pharmaceutical Co., Ltd. Patentee before: Zhang Zhongyi |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20041124 Termination date: 20211219 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |